Vicki Moore, PhD

Contributing Writer https://www.hematologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

Tan pills spilling out of a bottle.

Sorafenib Maintenance Post-Transplantation for FLT3-ITD Acute Myeloid Leukemia

By

Vicki Moore, PhD

September 28, 2020

Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.

5-azacitidine may lead to sustained response in peripheral T-cell lymphoma.

Myelodysplastic Syndromes

Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome

By

Vicki Moore, PhD

September 28, 2020

For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.

Analysis of Carfilzomib vs Bortezomib Triplet Therapy for Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

September 25, 2020

The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.

General Hematology

Siltuximab for Patients With Idiopathic Multicentric Castleman Disease

By

Vicki Moore, PhD

September 25, 2020

Researchers evaluated an approach to treatment guided by histopathologic subtype in patients with idiopathic multicentric Castleman disease.

Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

By

Vicki Moore, PhD

September 22, 2020

An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.

Assisting a patient while barged to prevent infection.

General Hematology

Communicating With Patients in Oncology About Care During the COVID-19 Pandemic

By

Vicki Moore, PhD

September 17, 2020

How to explain adjustments to cancer care due to the COVID-19 pandemic and ease patients’ fears about the impact of those changes.

Researchers analyzed long-term follow-up data from 2 clinical trials.

Low-Dose Anti-PD1 Therapies in Relapsed/Refractory Classical Hodgkin Lymphoma

By

Vicki Moore, PhD

September 4, 2020

A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.

Pediatrician with patient and parent

General Hematology

Glycemic Variability and Pediatric Hematopoietic Stem Cell Transplantation

By

Vicki Moore, PhD

September 4, 2020

Glycemic variability is suggested to be a risk factor for complications with hematopoietic stem cell transplantation in pediatric patients.

Outcomes for Adolescents With Acute Lymphoblastic Leukemia

By

Vicki Moore, PhD

September 3, 2020

Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.

Lipid Microenvironment With B-Cell Lymphoma and Natural Killer Cell Function

By

Vicki Moore, PhD

September 3, 2020

Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.

Next post in Lymphoma

Reviewing the care plan for a young patient.

Trends Suggest More AYA Lymphoma Survivors Being Engaged in Survivorship Discussions, But Improvements Needed